| OCR Text |
Show 272 Comparison of Visual Outcomes and Optic coherence tomography (OCT) in acute or sub acute Non-Arteritic Ischemic Optic Neuropathy (NAAION) with and without Bevacizumab treatment Ramesh Kekunnaya 1, Virender Sachdeva 2 1 L V Prasad Eye Institute, KAR Campus, 2 L V Prasad Eye Institute, GMRV Campus Introduction: To compare visual outcomes and Optical coherence tomography (OCT) changes in patients with intravitreal Bevacizumab vs. no treatment in patients with acute or sub-acute non-arteritic ischemic optic neuropathy (NAAION). Methods: Retrospective review of records of patients with acute (< 15 days) or sub-acute NAAION who were treated with intravitreal Bevacizumab injection (group A) versus no treatment (group B) from January 1, 2020, to December 31, 2023, at our institute. Data was collected regarding patient demographics, visual function, and OCT parameters at presentation and follow-up visits. Results: A total of 39 eyes of 37 Patients with NAAION (26 group A and 13 group B) were identified. Median age of patients was 50 (IQR:43-58) years and 44 (IQR: 42-53) years in groups A and B respectively, p (0.25). There was no statistically significant difference in gender, presenting visual acuity, disc edema grade, visual field mean deviation, coexisting macular edema. However, the average duration of symptoms was 7 days vs 20 days in groups A and B respectively. The average thickness of peripapillary RNFL was more in group A (312: IQR: 198-356 microns) vs. 140 (IQR: 117-265) microns, p-0.008. The average improvement in best corrected visual acuity, BCVA was 0.2 (IQR:0.1-0.5) logMAR in group A vs. 0(IQR: -0.3 to 0) logMAR in group B. p=0.0008. Improvement in foveal sensitivity was 4.5(IQR: 0 to 9) db in group A vs. -3(-8 to 2 dB) in group B, p =0.008. Regression analysis showed intervention (bevacizumab vs. no treatment) and presenting visual acuity were the only factors that affected improvement in BCVA and visual field foveal sensitivity. . Conclusions: The current study suggests that patients with acute/subacute NAAION treated with intravitreal Avastin might have a greater improvement in final BCVA and foveal sensitivity. However, prospective more robust studies might be needed to validate these results. References: None provided. Keywords: Optic neuropathy, Diagnostic tests (ERG, VER, OCT, HRT, mfERG, etc), Vascular disorders, Miscellaneous Financial Disclosures: The authors had no disclosures. Grant Support: HERF Contact Information: Ramesh Kekunnaya, rameshak@lvpei.org 432 | North American Neuro-Ophthalmology Society |
